A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – Radiopharmaceutical company Nuclidium has raised $99 million in Series B financing to advance its copper-61 and copper-67 theranostics, the firm announced Thursday. The round was led by ...